2m 2m 2m 2m 2m 2m 2m
Intl Stem Cell (ISCO)
OTC
$0.18+$0.007 (+3.88%)
Price as of Jun 03, 2026- $1.4MMarket Cap
- 22.68%1-Year Change
- BiotechnologyIndustry
Intl Stem Cell (ISCO)
$0.18+$0.007 (+3.88%)
Annual
Quarterly
12/31/2025 | 12/31/2024 | 12/31/2023 | 12/31/2022 | ||
|---|---|---|---|---|---|
Income Statement | |||||
Total Operating Revenue | 9.1M +0.17% | 9.1M +16.64% | 7.8M -4.78% | 8.2M +13.99% | |
Cost of Revenue | 4.0M +7.15% | 3.8M +18.33% | 3.2M -2.69% | 3.3M +11.38% | |
Gross Profit | 5.1M -4.77% | 5.3M +15.47% | 4.6M -6.17% | 4.9M +15.80% | |
Sales and Marketing Expense | 1.1M -8.06% | 1.2M -2.41% | 1.2M +0.08% | 1.2M -9.98% | |
Research and Development Expense | -684,000 +4.11% | -657,000 +28.57% | -511,000 +3.86% | -492,000 -29.21% | |
Depreciation and Amortization Expense | 219,000 +6.31% | 206,000 +6.19% | 194,000 -11.01% | 218,000 -16.79% | |
Total Operating Expenses | 9.4M +2.34% | 9.2M +8.29% | 8.5M +1.06% | 8.4M -8.07% | |
Operating Profit | -267,000 +292.65% | -68,000 -89.74% | -663,000 +262.30% | -183,000 -90.47% | |
Interest Income | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Interest Expense | -6,000 -95.86% | -145,000 +4.32% | -139,000 +2.96% | -135,000 +5.47% | |
Interest Income and Expense and Net | -6,000 -95.86% | -145,000 +4.32% | -139,000 +2.96% | -135,000 +5.47% | |
Total Nonoperating Income and Expense | -151,000 +7.09% | -141,000 -126.50% | 532,000 +459.46% | -148,000 -114.48% | |
Income before Taxes | -267,000 +292.65% | -68,000 -89.74% | -663,000 +262.30% | -183,000 -90.47% | |
Income Taxes | 0 N/A | N/A N/A | N/A N/A | N/A N/A | |
Extraordinary Items | N/A N/A | N/A N/A | 0 N/A | 0 N/A | |
Net Income | -418,000 +100.00% | -209,000 +59.54% | -131,000 -60.42% | -331,000 -63.18% | |
Net Income from Continuing Operations Applicable to Common | -418,000 +100.00% | -209,000 +59.54% | -131,000 -60.42% | -331,000 -63.18% | |
Basic EPS and Net Income | -0.05 +66.67% | -0.03 +50.00% | -0.02 -50.00% | -0.04 -63.64% | |
Diluted EPS and Net Income | -0.05 +66.67% | -0.03 +50.00% | -0.02 -50.00% | -0.04 -63.64% | |
Basic Weighted Average Shares | 8.0M 0.00% | 8.0M 0.00% | 8.0M +0.005% | 8.0M +2.18% | |
Diluted Weighted Average Shares | 8.0M 0.00% | 8.0M 0.00% | 8.0M +0.005% | 8.0M +2.18% | |
Balance Sheet | |||||
Cash and Cash Equivalents | 993,000 -19.27% | 1.2M -22.54% | 1.6M +114.02% | 742,000 +333.92% | |
Short-Term Investments | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cash and Cash Equivalents and Short-Term Investments | 993,000 -19.27% | 1.2M -22.54% | 1.6M +114.02% | 742,000 +333.92% | |
Total Current Assets | 3.4M -4.19% | 3.6M +1.11% | 3.5M +18.83% | 3.0M +26.95% | |
Accumulated Depreciation | 2.5M +5.46% | 2.3M +0.04% | 2.3M +4.82% | 2.2M +4.52% | |
Property and Plant and Equipment and Net | 160,000 -37.74% | 257,000 +19.53% | 215,000 -13.31% | 248,000 -35.42% | |
Total Long-Term Assets | 160,000 -37.74% | 257,000 +19.53% | 215,000 -13.31% | 248,000 -35.42% | |
Total Assets | 4.8M -6.84% | 5.2M -4.03% | 5.4M +4.97% | 5.1M +3.82% | |
Income Taxes Payable | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Short-Term Debt | 3.3M -1.62% | 3.4M -1.79% | 3.5M +3.97% | 3.3M +12.98% | |
Total Current Liabilities | 4.6M -2.33% | 4.7M -2.98% | 4.8M +4.25% | 4.6M +8.19% | |
Total Long-Term Debt | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Long-Term Liabilities | 0 -100.00% | 115,000 -74.16% | 445,000 -38.19% | 720,000 -24.21% | |
Total Liabilities | 4.6M -4.66% | 4.8M -8.98% | 5.3M -1.46% | 5.4M +2.31% | |
Retained Earnings | -111.1M +0.38% | -110.7M +0.19% | -110.5M +0.12% | -110.3M +0.30% | |
Total Stockholders Equity | -4.1M +3.31% | -3.9M -6.14% | -4.2M -7.37% | -4.5M -1.48% | |
Total Shares Outstanding | 8.0M 0.00% | 8.0M 0.00% | 8.0M 0.00% | 8.0M 0.00% | |
Cash Flow | |||||
Cash from Operating Activities | 8,000 -38.46% | 13,000 -98.60% | 929,000 +179.82% | 332,000 +125.60% | |
Capital Expenditures | 43,000 -74.10% | 166,000 +107.50% | 80,000 +7,900.00% | 1,000 -95.65% | |
Cash from Investing Activities | -45,000 -73.68% | -171,000 +106.02% | -83,000 +654.55% | -11,000 -75.56% | |
Dividends Paid | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cash from Financing Activities | -200,000 0.00% | -200,000 -180.00% | 250,000 0.00% | 250,000 -69.66% | |
Financials Ratio | |||||
Gross Margin | 55.68% -4.93% | 58.57% -1.00% | 59.16% -1.46% | 60.04% +1.59% | |
Operating Margin | -2.93% +292.00% | -0.75% -91.21% | -8.51% +280.48% | -2.24% -91.64% | |
Return on Assets | -8.37% +111.43% | -3.96% +58.97% | -2.49% -62.09% | -6.57% -62.63% | |
Return on Equity | 10.46% +103.18% | 5.15% +71.14% | 3.01% -58.60% | 7.27% -63.94% | |
Revenue Growth | 0.17% -99.01% | 16.64% +448.09% | -4.78% -134.16% | 13.99% +1,977.68% | |
Current Ratio | 0.74 -1.91% | 0.76 +4.21% | 0.73 +13.98% | 0.64 +17.35% | |
Cash Ratio | 0.22 -17.34% | 0.26 -20.15% | 0.33 +105.25% | 0.16 +301.25% | |
Debt-to-Equity Ratio | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Debt-to-Assets Ratio | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Earnings & Revenue History
Debt-to-Assets
Cash Flow